跳至主要内容
临床试验/NCT03422614
NCT03422614招募中不适用

Pathophysiologie Angeborener Immundefekte

University of Zurich2 个研究点 分布在 1 个国家目标入组 300 人开始时间: 2015年3月1日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
招募中
入组人数
300
试验地点
2
主要终点
Characterisation of cellular phenotype in different PIDs

研究概览

简要总结

The pathophysiology of primary immunodeficiencies (PID), which encompass a broad range of different diseases with susceptibility to infection and/or a deregulated inflammatory response, is poorly understood. Available treatments are often not specific for a distinct target and might be associated with side effects. To elucidate pathophysiology of different PIDs, stool, urine, blood, tissue biopsies and/or bone marrow will be collected and analysed for anti-microbial activity and inflammatory response. In a second step, targeted treatment for different PIDs might be developed preclinically and ex vivo according to underlying pathophysiology.

研究设计

研究类型
Observational
观察模型
Case Control
时间视角
Prospective

入排标准

性别
All
接受健康志愿者

入选标准

  • Clinical diagnosis of an inborn error of immunity (primary immunodeficiency, PID)
  • Clinically healthy (non-age matched) volunteer

排除标准

  • exclusion of an inborn error of immunity
  • secondary immunodeficiency
  • refusal to enter the study

研究组 & 干预措施

Patient

Patients with Primary Immunodeficiency

干预措施: Diagnostic Test (Diagnostic Test)

Control

Healthy Controls

干预措施: Diagnostic Test (Diagnostic Test)

结局指标

主要结局

Characterisation of cellular phenotype in different PIDs

时间窗: immediately after sampling of biological specimen or up to 10 years later from frozen samples

Immune cell subsets will be analysed for Surface marker Expression or cell activation pathways

Characterisation of functional phenotype in different PIDs

时间窗: immediately after sampling of biological specimen or up to 10 years later from frozen samples

Immune cell subsets will be analysed for cytokine production or cell activation pathways

次要结局

  • Identification of potential targets for pathophysiology-specific treatment, or for curative treatment such as gene therapy for different PIDs ex vivo(immediately after sampling of biological specimen or up to 10 years later from frozen samples)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Janine Reichenbach

Co-Head Division Immunology

University of Zurich

研究点 (2)

Loading locations...

相似试验